ANTITUMOR ACTIVITY OF PI3K ANTAGONIST AEZS126*IN MODELS OF TRIPLE NEGATIVE BREAST CANCER

被引：0
|
作者：
Engel, J. B. [1 ]
Schmidt, H. [1 ]
Haeussler, S. [1 ]
Diessner, J. [1 ]
Hahne, J. [1 ]
Meyer, S. [1 ]
Wischhusen, J. [1 ]
Dietl, J. [1 ]
Hoenig, A. [1 ]
机构：
[1] Univ Wurzburg, Dept Obstet & Gynecol, Wurzburg, Germany
来源：
ANTICANCER RESEARCH | 2011年 / 31卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1967 / 1968
页数：2
相关论文
共 50 条
  • [41] Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer
    Solzak, J. P.
    Atale, R.
    Hancock, B.
    Radovich, M.
    CANCER RESEARCH, 2016, 76
  • [42] Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer
    Jeffrey P. Solzak
    Rutuja V. Atale
    Bradley A. Hancock
    Anthony L. Sinn
    Karen E. Pollok
    David R. Jones
    Milan Radovich
    npj Breast Cancer, 3
  • [43] Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway
    Massihnia, Daniela
    Galvano, Antonio
    Fanale, Daniele
    Perez, Alessandro
    Castiglia, Marta
    Incorvaia, Lorena
    Listi, Angela
    Rizzo, Sergio
    Cicero, Giuseppe
    Bazan, Viviana
    Castorina, Sergio
    Russo, Antonio
    ONCOTARGET, 2016, 7 (37) : 60712 - 60722
  • [44] DNA copy number changes in the PI3K signaling pathway genes in triple negative breast cancer
    Oliveira, Marcia C.
    Pereira, Silma R.
    Ribeiro, Enilze M. F.
    Lima, Rubens S.
    Urban, Cicero A.
    Sebastiao, Ana Paula M.
    Marian, Catalin
    Haddad, Bassem R.
    Cavalli, Iglenir J.
    Cavalli, Luciane R.
    CANCER RESEARCH, 2011, 71
  • [45] Novel tumor suppressor regulating the PI3K/AKT pathway in triple negative breast cancer (TNBC)
    Chan, Stefanie
    Smith, Emma
    Monti, Stefano
    Cardamone, M. Dafne
    Perissi, Valentina
    CANCER RESEARCH, 2020, 80 (04)
  • [46] Combined Blockade of PI3K/AKT and EGFR/HER3 Enhances Anti-Tumor Activity in Triple Negative Breast Cancer
    Tao, J.
    Ip, P.
    Auricchio, N.
    Juric, D.
    Yu, M.
    Shyamala, M.
    Kim, P.
    Singh, S.
    Hazra, S.
    Haber, D.
    Scaltriti, M.
    Baselga, J.
    CANCER RESEARCH, 2012, 72
  • [47] Antitumor activity of CUDC-907, a dual PI3K and HDAC inhibitor, in hematological cancer models
    Rudi, Bao
    Wang, Dagong
    Qu, Hui
    Yin, Ling
    Zifcak, Brian
    DellaRocca, Steven
    Xu, Guang-Xin
    Borek, Mylissa
    Samson, Maria
    Atoyan, Ruzanna
    Poll, Anne
    Wang, Jing
    Zhai, Hai-Xaio
    Lai, Cheng-Jung
    Pepicelli, Carmen
    Cai, Xiong
    Qian, Changgeng
    CANCER RESEARCH, 2012, 72
  • [48] Molecular Pathways: PI3K Pathway Targets in Triple-Negative Breast Cancers
    Gordon, Vallerie
    Banerji, Shantanu
    CLINICAL CANCER RESEARCH, 2013, 19 (14) : 3738 - 3744
  • [49] Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R
    de Lint, Klaas
    Poell, Jos B.
    Soueidan, Hayssam
    Jastrzebski, Katarzyna
    Rodriguez, Jordi Vidal
    Lieftink, Cor
    Wessels, Lodewyk F. A.
    Beijersbergen, Roderick L.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (07) : 1545 - 1556
  • [50] Abrogating Metastatic Properties of Triple-Negative Breast Cancer Cells by EGFR and PI3K Dual Inhibitors
    Garcia, Ana Rita
    Mendes, Avilson
    Custodia, Carlos
    Faria, Claudia C.
    Barata, Joao T.
    Malho, Rui
    Figueira, Ines
    Brito, Maria Alexandra
    CANCERS, 2023, 15 (15)
12345